Browsing by Author "Unal, A"

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    Effects of Parenteral Papaverine and Piracetam Administration on Cochlea Following Acoustic Trauma
    Kum, NY; Yilmaz, YF; Gurgen, SG; Kum, RO; Ozcan, M; Unal, A
    Introduction: Noise exposure, the main cause of hearing loss in countries with lot of industries, may result both in temporary or permanent hearing loss. The goal of this study was to investigate the effects of parenteral papaverine and piracetam administration following an acoustic trauma on hearing function with histopathologic correlation. Materials and Methods: Eighteen Wistar albino rats exposed to noise for 8 h in a free environment were included. We divided the study population into three groups, and performed daily intraperitoneal injections of papaverine, piracetam, and saline, respectively, throughout the study. We investigated the histopathologic effects of cellular apoptosis on inner hair cells (IHCs) and outer hair cells (OHCs) and compared the distortion product otoacoustic emissions (DPOAEs) thresholds among the groups. Results and Discussion: On the 3rd and 7th days, DPOAE thresholds at 8 kHz were significantly higher both in papaverine and piracetam groups compared with the control group (P = 0.004 for 3rd day, P = 0.016 and P = 0.028 for 7th day, respectively). On the 14th day, piracetam group had significantly higher mean thresholds at 8 kHz (P = 0.029); however, papaverine group had similar mean thresholds compared to the control group (P = 0.200). On the 3rd and 7th days following acoustic trauma, both IHC and OHC loss were significantly lower in both papaverine and piracetam groups. On the 7th day, the mean amount of apoptotic IHCs and OHCs identified using Caspase-3 method were significantly lower in both groups, but the mean amount identified using terminal deoxynucleotidyl transferase dUTP nick end labeling method were similar in both groups compared to the control group. Conclusion: We demonstrated the effects of papaverine and piracetam on the recovery of cochlear damage due to acoustic trauma on experimental animals using histopathologic and electrophysiologic examinations.
  • No Thumbnail Available
    Item
    Evolution of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in turkey: a multicenter retrospective analysis
    Karadag, FK; Yenerel, MN; Yilmaz, M; Uskudar, H; Ozkocaman, V; Tuglular, TF; Erdem, F; Unal, A; Ayyildiz, O; Ozet, G; Comert, M; Kaya, E; Ayer, M; Salim, O; Guvenc, B; Ozdogu, H; Mehtap, O; Sonmez, M; Guler, N; Hacioglu, S; Aydogdu, I; Bektas, O; Toprak, SK; Kaynar, L; Yagci, M; Aksu, S; Tombak, A; Karakus, V; Yavasoglu, I; Onec, B; Ozcan, MA; Undar, L; Ali, R; Ilhan, O; Saydam, G; Sahin, F
    Paroxysmal nocturnal hemoglobinuria (PNH) is a rare X-linked genetic disorder. On the contrary to its name, it is a multisystemic disease and various symptoms other than hemoglobinuria could be occurred. It could be life threatening especially because of thromboembolic events. In the last decade, a terminal complement inhibition with eculizumab approved with promising results for PNH patients. We conducted this study to evaluate the long term experience of eculizumab therapy from Turkey for the first time. Our cohort included 138 patients with PNH treated with eculizumab between January 2008 and December 2018 at 28 centers in Turkey. Laboratory and clinical findings at the time of diagnosis and after eculizumab therapy were recorded retrospectively. The median age was 39 (range 18-84) years and median granulocyte PNH clone size was 74% (range 3.06-99.84%) at the time of diagnosis. PNH with bone marrow failure syndrome was detected in 49 patients and the rest of 89 patients had classical PNH. Overall 45 patients (32.6%) had a history of any prior thrombotic event before eculizumab therapy and only 2 thrombotic events were reported during the study period. Most common symptoms are fatigue (75.3%), hemoglobinuria (18.1%), abdominal pain (15.2%) and dysphagia (7.9%). Although PNH is commonly related with coombs negativity, we detected coombs positivity in 2.17% of patients. Seven months after the therapy, increased hemoglobin level was seen and remarkably improvement of lactate dehydrogenase level during the treatment was occurred. In addition to previous studies, our real life data support that eculizumab is well tolerated with no serious adverse events and improves the PNH related findings.
  • No Thumbnail Available
    Item
    Efficacy and Safety of Ibrutinib Use in Patients with Chronic Lymphocytic Leukemia in Real World Experiences: Results of a Prospective Multicenter Study
    Tombak, A; Tanrikulu, FP; Durusoy, SS; Gurkan, E; Kaya, E; Umit, EG; Yavasoglu, I; Mehtap, O; Deveci, B; Ozcan, MA; Terzi, H; Okay, M; Sayinalp, N; Yilmaz, M; Okan, V; Kizikli, A; Ozcan, O; Cetin, G; Demircioglu, S; Aydogdu, I; Saydam, G; Davulcu, EA; Ilhan, G; Ucar, MA; Ozet, G; Akpinar, S; Turgut, B; Berber, I; Kurtoglu, E; Sonmez, M; Batur, DS; Yildirim, R; Ozkocaman, V; Gunes, AK; Sahip, B; Ertop, S; Akay, M; Basturk, A; Dogu, MH; Akdeniz, A; Unal, A; Seyhanli, A; Ferhanoglu, B
  • No Thumbnail Available
    Item
    Evaluation of Patients with PNH Treated By Eculizumab: Real World Data from Turkey
    Karadag, FK; Yenerel, MN; Mehmet, Y; Teke, HU; Ozkocaman, V; Tuglular, T; Erdem, F; Unal, A; Ayyildiz, O; Ozet, G; Ozkan, M; Kaya, E; Ayer, M; Salim, O; Güvenç, B; Ozdogu, H; Mehtap, Ö; Sönmez, M; Güler, N; Hacioglu, SK; Aydogdu, I; Bektas, O; Toprak, SK; Kaynar, L; Yagci, M; Aksu, S; Tombak, A; Karakus, V; Yavasoglu, I; Öneç, B; Özcan, MA; Ündar, L; Ali, R; Ustun, C; Ilhan, O; Saydam, G; Sahin, F